
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Be alert for the signs of peripheral vascular disease, Anna Falabella, M.D., said at the annual meeting of the American Academy of Dermatology.